These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332 [TBL] [Abstract][Full Text] [Related]
7. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas. Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205 [TBL] [Abstract][Full Text] [Related]
8. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study. Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088 [TBL] [Abstract][Full Text] [Related]
10. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma. Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044 [TBL] [Abstract][Full Text] [Related]
11. Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review. Oh KY Oral Oncol; 2023 Nov; 146():106585. PubMed ID: 37816291 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review. Yoithapprabhunath TR; Srichinthu KK; Gupta D; Singh D; Pasupuleti S; Nirmal RM Indian J Dent Res; 2022; 33(3):323-331. PubMed ID: 36656197 [TBL] [Abstract][Full Text] [Related]
13. Association of MDM2 Overexpression in Ameloblastomas with Tosios KI; Kalogirou EM; Koutlas IG Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916 [TBL] [Abstract][Full Text] [Related]
14. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340 [TBL] [Abstract][Full Text] [Related]
15. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution. Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892 [No Abstract] [Full Text] [Related]
16. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma]. Yan XC; Sun LS; Dong ZW; You Z; Dong Q Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373 [TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical and genetic study of BRAF Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640 [TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution. Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757 [TBL] [Abstract][Full Text] [Related]
20. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population. Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]